Year archive

Luye Pharma Group Limited — 2021 filings

All 133 regulatory filings released by Luye Pharma Group Limited (2186) in 2021, sourced directly from the official regulator.

133 Filings

2021 Period

2021 filings (133)

Filing	Released	Lang
ACCEPTANCE OF APPLICATION FOR MARKETING AUTHORIZATION IN CHINA FOR GOSERELIN ACETATE EXTENDED-RELEASE MICROSPHERES FOR INJECTION (LY01005) Regulatory Filings	2021-12-29	English
VOLUNTARY ANNOUNCEMENT - LUYE PHARMA GRANTED EXCLUSIVE COMMERCIALIZATION RIGHTS OF RIVASTIGMINE TRANSDERMAL PATCH IN THE MAINLAND OF CHINA TO GENSCI Capital/Financing Update	2021-12-22	English
List of Directors and their Roles and Functions Board/Management Information	2021-12-15	English
APPOINTMENT AND RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS Board/Management Information	2021-12-15	English
VOLUNTARY ANNOUNCEMENT - APPROVAL OBTAINED FOR INITIATING CLINICAL TRIAL FOR THE GROUP'S INNOVATIVE ANTIBODY DRUG BA1201 IN CHINA Regulatory Filings	2021-12-14	English
Interim Report 2021 Interim / Quarterly Report H1 2021	2021-12-13	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021 Regulatory Filings	2021-12-03	English
Monthly Return of Equity Issuer on Movements in Securities Regulatory Filings	2021-12-01	English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021 Interim / Quarterly Report H1 2022	2021-11-29	English
CHANGE OF INFORMATION OF DIRECTOR Board/Management Information	2021-11-19	English
NOTICE OF BOARD MEETING Regulatory Filings	2021-11-17	English
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION SUBMITTED IN THE U.S. FOR THE GROUP'S NEW DRUG LY03009 Regulatory Filings	2021-11-15	English
VOLUNTARY ANNOUNCEMENT - LUYE PHARMA GRANTED EXCLUSIVE RIGHTS TO COMMERCIALIZE NEW DRUG RIVASTIGMINE MD IN SWITZERLAND TO ZAMBON Regulatory Filings	2021-11-10	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021 Regulatory Filings	2021-11-03	English
Monthly Return of Equity Issuer on Movements in Securities Regulatory Filings	2021-11-01	English
VOLUNTARY ANNOUNCEMENT - APPROVAL OBTAINED FOR INITIATING CLINICAL TRIAL FOR THE GROUP'S NEW DRUG LY03009 IN CHINA Regulatory Filings	2021-10-27	English
INSIDE INFORMATION - ARBITRATION AWARD Legal Proceedings Report	2021-10-22	English
VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORIZATION APPLICATION FOR DENOSUMAB INJECTION (LY06006/BA6101) ACCEPTED IN CHINA Regulatory Filings	2021-10-13	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2021 Regulatory Filings	2021-10-05	English
Monthly Return of Equity Issuer on Movements in Securities Regulatory Filings	2021-10-04	English
VOLUNTARY ANNOUNCEMENT - APPROVAL OBTAINED FOR INITIATING CLINICAL TRIAL FOR THE GROUP'S INNOVATIVE ANTIBODY DRUG BA1105 IN CHINA Regulatory Filings	2021-10-04	English
DISCLOSEABLE TRANSACTION - COMPLETION OF THIRD PARTIES' INVESTMENTS IN BOAN BIOTECH Capital/Financing Update	2021-09-30	English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR INITIATING CLINICAL TRIAL FOR CLASS 1 NEW DRUG LY03015 Regulatory Filings	2021-09-29	English
Interim Report 2021 Interim / Quarterly Report H1 2021	2021-09-29	English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR INITIATING CLINICAL TRIAL FOR DULAGLUTIDE INJECTION (BA5101) IN CHINA Regulatory Filings	2021-09-27	English
VOLUNTARY ANNOUNCEMENT - THE NEW DRUG RIVASTIGMINE MD RECEIVED MARKETING AUTHORIZATION IN THE UK Regulatory Filings	2021-09-23	English
DISCLOSEABLE TRANSACTION - THIRD PARTIES' INVESTMENTS IN BOAN BIOTECH Capital/Financing Update	2021-09-13	English
VOLUNTARY ANNOUNCEMENT - LUYE PHARMA GRANTS EXCLUSIVE RIGHTS TO COMMERCIALIZE NEW DRUG RIVASTIGMINE MD IN SPAIN TO ESTEVE Regulatory Filings	2021-09-08	English
Monthly Return of Equity Issuer on Movements in Securities Regulatory Filings	2021-09-06	English
VOLUNTARY ANNOUNCEMENT - GOSERELIN ACETATE EXTENDED-RELEASE MICROSPHERES FOR INJECTION (LY01005) COMPLETED PHASE III CLINICAL TRIAL FOR THE TREATMENT OF PROSTATE CANCER IN CHINA Regulatory Filings	2021-09-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021 Regulatory Filings	2021-09-03	English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2020/21 Environmental & Social Information	2021-08-31	English
Monthly Return of Equity Issuer on Movements in Securities Regulatory Filings	2021-08-31	English
Monthly Return of Equity Issuer on Movements in Securities Share Issue/Capital Change	2021-08-30	English
Next Day Disclosure Return Share Issue/Capital Change	2021-08-30	English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 Interim / Quarterly Report H1 2021	2021-08-29	English
RESULTS OF THE RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHT SHARES FOR EVERY ONE (1) SHARE HELD ON RECORD DATE Capital/Financing Update	2021-08-27	English
DISCLOSEABLE TRANSACTION - THIRD PARTIES INVESTMENTS IN BOAN BIOTECH Capital/Financing Update	2021-08-26	English
VOLUNTARY ANNOUNCEMENT - NEW INDICATION APPROVED FOR BOYOUNUO (BEVACIZUMAB INJECTION) IN CHINA Regulatory Filings	2021-08-23	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 23 AUGUST 2021 Declaration of Voting Results & Voting Rights Announcements	2021-08-23	English
VOLUNTARY ANNOUNCEMENT - UPDATED PROGRESS IN RELATION TO NEUTRALIZING ANTIBODY AGAINST SARS-COV-2 Regulatory Filings	2021-08-20	English
APPLICATIONS FOR THE RIGHTS SHARES AND NUMBER OF UNSUBSCRIBED RIGHTS SHARES SUBJECT TO THE COMPENSATORY ARRANGEMENTS Capital/Financing Update	2021-08-18	English
NOTICE OF BOARD MEETING Regulatory Filings	2021-08-17	English
Monthly Return of Equity Issuer on Movements in Securities Major Shareholding Notification	2021-08-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021 Regulatory Filings	2021-08-03	English
Provisional Allotment Letter Capital/Financing Update	2021-08-02	English
PROPOSED RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHTS SHARES FOR EVERY ONE (1) SHARE HELD ON THE RECORD DATE Capital/Financing Update	2021-08-02	English
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION SUBMITTED IN THE U.S. FOR THE GROUP'S NEW DRUG LY03015 Regulatory Filings	2021-08-02	English
VOLUNTARY ANNOUNCEMENT - NEW INDICATION APPROVED FOR BOYOUNUO (BEVACIZUMAB INJECTION) IN CHINA Regulatory Filings	2021-07-28	English
Form of proxy for use by shareholders at the Annual General Meeting to be convened on Monday, 23 August 2021 at 10:00 a.m. AGM Information	2021-07-26	English
NOTICE OF ANNUAL GENERAL MEETING AGM Information	2021-07-26	English
GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF DIRECTORS; RE-APPOINTMENT OF INDEPENDENT AUDITOR; AND NOTICE OF ANNUAL GENERAL MEETING AGM Information	2021-07-26	English
Annual Report 2020/21 Annual Report FY 2021	2021-07-26	English
Environmental, Social and Governance Report 2020 Environmental & Social Information	2021-07-22	English
(1) POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 13 JULY 2021; AND (2) GRANT OF WHITEWASH WAIVER Declaration of Voting Results & Voting Rights Announcements	2021-07-13	English
REVISED EXPECTED TIMETABLE IN RELATION TO (I) PROPOSED CAPITAL REORGANISATION; (II) PROPOSED CHANGE IN BOARD LOT SIZE; (III) PROPOSED RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHTS SHARES FOR Capital/Financing Update	2021-07-07	English
Monthly Return of Equity Issuer on Movements in Securities Share Issue/Capital Change	2021-07-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2021 Capital/Financing Update	2021-07-06	English
VOLUNTARY ANNOUNCEMENT - PROPOSED SPIN-OFF AND SEPARATE LISTING OF BOAN BIOTECH Capital/Financing Update	2021-07-02	English
DESPATCH OF CIRCULAR IN RELATION TO (I) PROPOSED CAPITAL REORGANISATION; (II) PROPOSED CHANGE IN BOARD LOT SIZE; (III) PROPOSED RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHTS SHARES FOR EVERY Capital/Financing Update	2021-06-21	English
Form of proxy for use by shareholders at the Special General Meeting to be convened at 10:00 a.m. on Tuesday, 13 July 2021 Proxy Solicitation & Information Statement	2021-06-21	English
(I) PROPOSED CAPITAL REORGANISATION; (II) PROPOSED CHANGE IN BOARD LOT SIZE; (III) PROPOSED RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHTS SHARES FOR EVERY ONE (1) ADJUSTED SHARE HELD ON THE Proxy Solicitation & Information Statement	2021-06-21	English
NOTICE OF SPECIAL GENERAL MEETING Proxy Solicitation & Information Statement	2021-06-21	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 16 JUNE 2021 Declaration of Voting Results & Voting Rights Announcements	2021-06-16	English
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL APPLICATION SUBMITTED IN THE U.S. FOR NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2 Regulatory Filings	2021-06-15	English
VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORIZATION APPLICATION FOR CLASS 1 NEW DRUG ANSHUFAXINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS (LY03005) ACCEPTED IN CHINA Regulatory Filings	2021-06-10	English
MONTHLY UPDATE ANNOUNCEMENT ON (I) PROPOSED CAPITAL REORGANISATION; (II) PROPOSED CHANGE IN BOARD LOT SIZE; (III) PROPOSED RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHTS SHARES FOR EVERY ONE Capital/Financing Update	2021-06-10	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2021 Annual Report FY 2021	2021-06-10	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2021 Annual Report FY 2021	2021-06-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021 Regulatory Filings	2021-06-04	English
Monthly Return of Equity Issuer on Movements in Securities Share Issue/Capital Change	2021-06-04	English
VOLUNTARY ANNOUNCEMENT - GRANTED THE EXCLUSIVE PROMOTION RIGHT OF BEVACIZUMAB INJECTION IN SPECIFIC COUNTY MARKETS OF CHINA TO ASTRAZENECA Regulatory Filings	2021-05-26	English
DATE OF BOARD MEETING Report Publication Announcement	2021-05-25	English
VOLUNTARY ANNOUNCEMENT - THE NEW DRUG RIVASTIGMINE MD IS ELIGIBLE FOR MARKETING AUTHORIZATION IN SEVERAL EU COUNTRIES Regulatory Filings	2021-05-24	English
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 16 JUNE 2021 AGM Information	2021-05-13	English
NOTICE OF ANNUAL GENERAL MEETING AGM Information	2021-05-13	English
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING AGM Information	2021-05-13	English
VOLUNTARY ANNOUNCEMENT - APPROVAL OBTAINED FOR INITIATING CLINICAL TRIAL FOR THE GROUP'S NEW DRUG LY09606 IN CHINA Regulatory Filings	2021-05-13	English
FURTHER DELAY IN DESPATCH OF CIRCULAR AND REVISED EXPECTED TIMETABLE IN RELATION TO (I) PROPOSED CAPITAL REORGANISATION; (II) PROPOSED CHANGE IN BOARD LOT SIZE; (III) PROPOSED RIGHTS ISSUE O Capital/Financing Update	2021-05-10	English
VOLUNTARY ANNOUNCEMENT - MARKETING REGISTRATION OF BEVACIZUMAB INJECTION APPROVED BY NMPA Regulatory Filings	2021-05-07	English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR INITIATING CLINICAL TRIAL FOR NIVOLUMAB INJECTION ("LY01015") IN CHINA Regulatory Filings	2021-05-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021 Share Issue/Capital Change	2021-05-06	English
VOLUNTARY ANNOUNCEMENT - NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2 COMPLETED PHASE I CLINICAL TRIAL IN CHINA Regulatory Filings	2021-05-06	English
Monthly Return of Equity Issuer on Movements in Securities Major Shareholding Notification	2021-05-03	English
Annual Report 2020 Annual Report FY 2020	2021-04-29	English
DELAY IN DESPATCH OF CIRCULAR IN RELATION TO (I) PROPOSED CAPITAL REORGANISATION; (II) PROPOSED CHANGE IN BOARD LOT SIZE; (III) PROPOSED RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHTS SHARES Regulatory Filings	2021-04-28	English
(I) PROPOSED CAPITAL REORGANISATION; (II) PROPOSED CHANGE IN BOARD LOT SIZE; (III) PROPOSED RIGHTS ISSUE ON THE BASIS OF THREE (3) RIGHTS SHARES FOR EVERY ONE (1) ADJUSTED SHARE HELD ON THE Capital/Financing Update	2021-04-08	English
Monthly Return of Equity Issuer on Movements in Securities Share Issue/Capital Change	2021-04-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021 Share Issue/Capital Change	2021-04-01	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020 Annual Report FY 2020	2021-03-31	English
VOLUNTARY ANNOUNCEMENT - A PHASE III CLINICAL TRIAL IN CHINA OF CLASS 1 NEW DRUG ANSHUFAXINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS (LY03005) IN THE TREATMENT OF MDD MET THE PREDEFINED ENDPOINTS Regulatory Filings	2021-03-25	English
CHANGE IN USE OF PROCEEDS FROM THE PLACING AND TOP-UP SUBSCRIPTION Capital/Financing Update	2021-03-19	English
VOLUNTARY ANNOUNCEMENT - CLASS 1 NEW DRUG LY03014 COMMENCED ENROLMENT OF SUBJECTS IN PHASE I CLINICAL TRIAL IN CHINA Regulatory Filings	2021-03-18	English
NOTICE OF BOARD MEETING Regulatory Filings	2021-03-16	English
VOLUNTARY ANNOUNCEMENT - LUYE PHARMA GRANTED EXCLUSIVE RIGHTS TO COMMERCIALIZE THE NEW DRUG RIVASTIGMINE MD IN FOUR EUROPEAN COUNTRIES TO ITALFARMACO Capital/Financing Update	2021-03-16	English
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION OF THE GROUP'S NEW DRUG LY09606 WAS FORMALLY ACCEPTED BY CDE Regulatory Filings	2021-03-07	English
Next Day Disclosure Return Regulatory Filings	2021-03-05	English
Monthly Return of Equity Issuer on Movements in Securities Share Issue/Capital Change	2021-03-05	English
COMPLETION OF THE ACQUISITION OF THE REMAINING SHARES OF THE TARGET COMPANY AND ISSUE AND ALLOTMENT OF THE CONSIDERATION SHARES UNDER THE SPECIFIC MANDATE Capital/Financing Update	2021-03-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021 Share Issue/Capital Change	2021-03-04	English
Monthly Return of Equity Issuer on Movements in Securities Share Issue/Capital Change	2021-03-03	English
POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 26 FEBRUARY 2021 Declaration of Voting Results & Voting Rights Announcements	2021-02-26	English
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION OF LY01015 HAS BEEN FORMALLY ACCEPTED BY CDE Regulatory Filings	2021-02-25	English
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT IN RELATION TO THE NEW DRUG RIVASTIGMINE MULTI-DAY TRANSDERMAL PATCH WITH TOWA PHARMACEUTICAL IN JAPAN Capital/Financing Update	2021-02-18	English
CHANGE OF VENUE OF SPECIAL GENERAL MEETING TO BE HELD ON 26 FEBRUARY 2021 Regulatory Filings	2021-02-09	English
Next Day Disclosure Return Share Issue/Capital Change	2021-02-08	English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION Board/Management Information	2021-02-08	English
ANNOUNCEMENT - (1) COMPLETION OF ISSUE OF NEW SHARES UNDER GENERAL MANDATE (2) COMPLETION OF SALE OF EXISTING SHARES BY CONTROLLING SHAREHOLDER AND (3) APPOINTMENT OF NON-EXECUTIVE DIRECTOR Capital/Financing Update	2021-02-08	English
Form of proxy for use by shareholders at the Special General Meeting to be convened on Friday, 26 February 2021 at 10:00 a.m. Proxy Solicitation & Information Statement	2021-02-08	English
NOTICE OF SPECIAL GENERAL MEETING Proxy Solicitation & Information Statement	2021-02-08	English
DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE PROPOSED ACQUISITION OF THE REMAINING ISSUED SHARE CAPITAL IN GBR (HK) LIMITED INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE Proxy Solicitation & Information Statement	2021-02-08	English
VOLUNTARY ANNOUNCEMENT - LY09004 COMPLETED THE FIRST PATIENT DOSING IN PHASE III CLINICAL TRIAL IN CHINA Regulatory Filings	2021-02-08	English
Next Day Disclosure Return Share Issue/Capital Change	2021-02-03	English
COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE Capital/Financing Update	2021-02-03	English
CHANGE OF AUDITOR Audit Report / Information FY 2021	2021-02-03	English
DISCLOSEABLE TRANSACTION - COMPLETION OF THIRD PARTIES INVESTMENTS IN SHANDONG BOAN Capital/Financing Update	2021-02-02	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021 Share Issue/Capital Change	2021-02-02	English
Monthly Return of Equity Issuer on Movements in Securities Share Issue/Capital Change	2021-02-01	English
ANNOUNCEMENT - (1) ISSUE OF NEW SHARES UNDER GENERAL MANDATE AND (2) SALE OF EXISTING SHARES BY CONTROLLING SHAREHOLDER Capital/Financing Update	2021-01-31	English
ANNOUNCEMENT - (1) PROPOSED ISSUE OF NEW SHARES UNDER GENERAL MANDATE AND (2) PROPOSED SALE OF EXISTING SHARES BY CONTROLLING SHAREHOLDER Capital/Financing Update	2021-01-29	English
SUPPLEMENTAL ANNOUNCEMENT - PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE Capital/Financing Update	2021-01-26	English
DISCLOSEABLE ANNOUNCEMENT - THIRD PARTIES' INVESTMENTS IN SHANDONG BOAN ADJUSTMENT TO THE TERMS OF THE SUBSCRIPTION Capital/Financing Update	2021-01-26	English
VOLUNTARY ANNOUNCEMENT - LY06006 COMPLETED THE LAST DOSING FOR ALL SUBJECTS IN PHASE III CLINICAL IN CHINA Regulatory Filings	2021-01-25	English
PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE Capital/Financing Update	2021-01-20	English
DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE PROPOSED ACQUISITION OF THE REMAINING 40% EQUITY INTEREST IN GBR (HK) LIMITED INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE Capital/Financing Update	2021-01-18	English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF SUBJECTS IN PHASE I CLINICAL TRIAL FOR NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2 IN CHINA Regulatory Filings	2021-01-18	English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION THIRD PARTIES' INVESTMENTS IN SHANDONG BOAN Capital/Financing Update	2021-01-18	English
VOLUNTARY ANNOUNCEMENT - ROTIGOTINE EXTENDED-RELEASE MICROSPHERES FOR INJECTION (LY03003) COMPLETED PHASE I CLINICAL TRIAL IN JAPAN Regulatory Filings	2021-01-15	English
VOLUNTARY ANNOUNCEMENT - MARKETING REGISTRATION OF RISPERIDONE MICROSPHERES FOR INJECTION (II) (LY03004) APPROVED BY NMPA Regulatory Filings	2021-01-14	English
Monthly Return of Equity Issuer on Movements in Securities Share Issue/Capital Change	2021-01-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020 Share Issue/Capital Change	2021-01-06	English
DISCLOSEABLE TRANSACTION - THIRD PARTIES' INVESTMENTS IN SHANDONG BOAN Capital/Financing Update	2021-01-04	English
VOLUNTARY ANNOUNCEMENT - LY03009 COMMENCED PHASE I CLINICAL TRIAL IN AUSTRALIA Regulatory Filings	2021-01-04	English

Filings by year

2026 23 filings
2025 87 filings
2024 87 filings
2023 95 filings
2022 105 filings
2021 133 filings
2020 108 filings
2019 105 filings
2018 134 filings
2017 105 filings
2016 68 filings
2015 79 filings
2014 69 filings
2013 23 filings
2012 27 filings
2011 24 filings
2010 26 filings
2009 27 filings
2008 22 filings
2007 24 filings
2006 23 filings
2005 37 filings
2004 14 filings
2003 14 filings
2002 12 filings
2001 20 filings
2000 13 filings
1999 6 filings